The US Food and Drug Administration (FDA) has granted 510(k) market clearance for South Korean developer of multiplex PCR technologies, Seegene‘s TOCE-based herpes simplex virus (HSV) types 1 and 2 assay.

According to the company, TOCE-based HSV assay is the first product that was taken through the FDA, and it opens the way for other planned FDA submissions of multiplex real-time PCR reagents.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company is planning to establish a new US subsidiary this year, and seeks to speed-up its growth in the global molecular diagnostic market.

Seegene founder Dr Jong-Yoon Chun said: "This is an important milestone in support of our planned entry into the United States, the largest molecular diagnostic market in the world.

"The company is focused on developing multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx)."

"After more than 10 years of extensive efforts to continually develop and commercialise novel technologies to surpass the capabilities of real-time PCR, we successfully invented MuDT technology, an ultimate multiplex real-time PCR technology that marks a new era in the molecular diagnostics industry.

"Through the US FDA approval, Seegene now intends to actively enhance its leadership in the multiplex real-time PCR diagnostic testing market."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will also continue to evolve its Allplex family of infectious disease panel tests for the US market.

Allplex tests are based on the company’s MuDT technology that enables simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis.

The company is focused on developing multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx).

M-MoDx tests, which are based on the company’s ACP, DPO, READ, TOCE, mTOCE and MuDT technologies, can simultaneously detect multiple targets with high-sensitivity, specificity and reproducibility.